中国当代医药
   March 15, 2025    Home                              中文
中国当代医药  2022, Vol. 29 Issue (10): 62-66转70    DOI:
Current Issue | Archive | Adv Search |
Effect of ST segment changes in lead aVR of patients with non-ST- segment elevation acute coronary syndrome
QIN Yuansheng1 TANG Xiu'e2
1.Department of Cardiology,the First Affiliated of Dalian Medical University,Liaoning Province,Dalian 116000,China;
2.Department of Cardiology,Dalian Jiche Hospital,Liaoning Province,Dalian 116000,China
Download: PDF (498 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  Objective To discuss the effect of ST segment changes in lead aVR of patients with non-ST-segment elevation acute coronary syndrome(NSTE-ACS).Methods A total of 168 patients with NSTE-ACS in the First Affiliated Hospital of Dalian Medical University from July 2019 to July 2020 were analyzed retrospectively,and divided into the non STaVR segment elevation group(65 cases),STaVR segment elevation 0.05-0.1 mV group(58 cases)and STaVR segment elevation ≥0.1 mV group(45 cases)according to the ST segment degree of improvement in lead aVR measurements at admission.The baseline data,occurrence of MACE within 6 months of three groups of patients were recorded and analyzed.Results The history of myocardial infarction,left ventricular ejection fraction(LVEF),Killip grade,number of diseased vessels and treatment regimen of the three groups were significant differences(P<0.05).The cTnI,CK-MB,BNP and hs-CRP levels of the three groups were significant differences(P<0.05);The cTnI,CK-MB,BNP and hs-CRP levels of STaVR segment elevation ≥0.1 mV group and STaVR segment elevation 0.05-0.1 mV group were higher than those of the non STaVR segment elevation group,the STaVR segment elevation ≥0.1 mV group were higher than the STaVR segment elevation 0.05-0.1 mV group,and the differences were statistically significant(P<0.05).The(repeat)myocardial infarction,cardiovascular death and revascularization incidence rates of the three groups within 6 months were significant different(P<0.05).The(repeat)myocardial infarction,cardiovascular death and revascularization incidence rates of the STaVR segment elevation ≥0.1 mV group and the STaVR segment elevation 0.05-0.1 mV group were higher than those of the non STaVR segment elevation group,the STaVR segment elevation ≥0.1 mV group were higher than the STaVR segment elevation 0.05-0.1 mV group,the differences were statistically significant(P<0.05).The distribution of non STaVR segment elevation,STaVR segment elevation 0.05-0.1 mV and STaVR segment elevation ≥0.1 mV of NSTE-ACS patients MACE occurrence or not within 6 months were significant differences(P<0.05).Multivariate logistic regression analysis showed that the LVEF(β=0.288,OR=1.586,95%CI=1.267-2.831),Killip classification(β=0.271, OR=1.716,95%CI=1.359-2.498),number of vessel branches(β=0.743, OR=2.247,95%CI=1.664-3.576),cTnI(β=0.553, OR=2.093,95%CI=1.537-3.498),CK-MB(β=1.105, OR=2.358,95%CI=1.239-3.869),BNP(β=0.934, OR=1.529,95%CI=0.913-2.722),hs-CRP(β=0.326, OR=1.768,95%CI=1.175-2.246)and STaVR segment elevation(β=0.179, OR=1.452,95%CI=1.123-2.051)were independent risk factors for MACE occurs within 6 months of NSTE-ACS patients(P<0.05).Conclusion The MACE incidence of NSTE-ACS patients with electrocardiogram STaVR segment elevation ≥0.1 mV is higher,moreover STaVR segment elevation is the independent risk factors for MACE occurs within 6 months in NSTE-ACS patients,which should be paid much attention.
Key wordsElectrocardiogram      Lead aVR      Non-ST-segment elevation acute coronary syndrome      Major adverse cardiac events     
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
QIN Yuansheng
TANG Xiu'e
Cite this article:   
QIN Yuansheng,TANG Xiu'e. Effect of ST segment changes in lead aVR of patients with non-ST- segment elevation acute coronary syndrome[J]. 中国当代医药, 2022, 29(10): 62-66转70.
URL:  
https://www.dangdaiyiyao.com/EN/     OR     https://www.dangdaiyiyao.com/EN/Y2022/V29/I10/62
Copyright © Editorial Board of 中国当代医药
Supported by:Beijing Magtech